Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: Ramos, Carlos A., Ballard, Brandon, Zhang, Huimin, Dakhova, Olga, Gee, Adrian P., Mei, Zhuyong, Bilgi, Mrinalini, Wu, Meng-Fen, Liu, Hao, Grilley, Bambi, Bollard, Catherine M., Chang, Bill H., Rooney, Cliona M., Brenner, Malcolm K., Heslop, Helen E., Dotti, Gianpietro, Savoldo, Barbara
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2017
Témata:
Clinical Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669573/
https://ncbi.nlm.nih.gov/pubmed/28805662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI94306
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky